WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H413121
CAS#: 39087-48-4
Description: Calcium Clofibrate is a calcium salt formulation of clofibrate, an aryloxyisobutyric acid derivate with antihyperlipidemic activity.
Hodoodo Cat#: H413121
Name: Calcium Clofibrate
CAS#: 39087-48-4
Chemical Formula: C20H20CaCl2O6
Exact Mass: 0.00
Molecular Weight: 467.350
Elemental Analysis: C, 51.40; H, 4.31; Ca, 8.58; Cl, 15.17; O, 20.54
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Calcium Clofibrate; EINECS 254-284-8; Calcii clofibras
IUPAC/Chemical Name: Calcium 2-(p-chlorophenoxy)-2-methylpropionate
InChi Key: IXCILCKRXAZYGP-UHFFFAOYSA-L
InChi Code: InChI=1S/2C10H11ClO3.Ca/c2*1-10(2,9(12)13)14-8-5-3-7(11)4-6-8;/h2*3-6H,1-2H3,(H,12,13);/q;;+2/p-2
SMILES Code: CC(C)(OC1=CC=C(Cl)C=C1)C([O-])=O.CC(C)(OC2=CC=C(Cl)C=C2)C([O-])=O.[Ca+2]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 467.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Klevay LM. Cholesterotropic and cuprotropic chemicals. J Sci Food Agric. 2020 Aug;100(10):4057. doi: 10.1002/jsfa.10426. Epub 2020 May 27. PMID: 32323867.
2: Oyagbemi AA, Adebiyi OE, Adigun KO, Ogunpolu BS, Falayi OO, Hassan FO, Folarin OR, Adebayo AK, Adejumobi OA, Asenuga ER, Ola-Davies OE, Omobowale TO, Olopade JO, Saba AB, Adedapo AA, Nkadimeng SM, McGaw LJ, Oguntibeju OO, Yakubu MA. Clofibrate, a PPAR-α agonist, abrogates sodium fluoride-induced neuroinflammation, oxidative stress, and motor incoordination via modulation of GFAP/Iba-1/anti-calbindin signaling pathways. Environ Toxicol. 2020 Feb;35(2):242-253. doi: 10.1002/tox.22861. Epub 2019 Nov 11. PMID: 31710167.
3: Endo M. Calcium-induced calcium release in skeletal muscle. Physiol Rev. 2009 Oct;89(4):1153-76. doi: 10.1152/physrev.00040.2008. PMID: 19789379.
4: Hays RM, Levine SD. Vasopressin. Kidney Int. 1974 Nov;6(5):307-22. doi: 10.1038/ki.1974.116. PMID: 4372455.
5: Azuma YT, Nishiyama K, Morioka A, Nakajima H, Takeuchi T. Clofibrate relaxes the longitudinal smooth muscle of the mouse distal colon through calcium- mediated desensitisation of contractile machinery. Pharmacology. 2011;88(1-2):65-71. doi: 10.1159/000329418. Epub 2011 Aug 16. PMID: 21846997.
6: Matzno S, Yasuda S, Kitada Y, Akiyoshi T, Tanaka N, Juman S, Shinozuka K, Nakabayashi T, Matsuyama K. Clofibrate-induced apoptosis is mediated by Ca2+-dependent caspase-12 activation. Life Sci. 2006 Mar 13;78(16):1892-9. doi: 10.1016/j.lfs.2005.08.003. Epub 2005 Oct 19. PMID: 16236330.
7: Lehtonen A, Viikari J. Effect of clofibrate and calcium in type II A hyperlipoproteinaemia. Acta Med Scand. 1977;202(3):179-81. doi: 10.1111/j.0954-6820.1977.tb16808.x. PMID: 333869.
8: Taylor T, Chasseaud LF. Plasma concentrations and bioavailability of clofibric acid from its calcium salt in humans. J Pharm Sci. 1977 Nov;66(11):1638-9. doi: 10.1002/jps.2600661138. PMID: 915750.
9: Lehtonen A, Viikari J. Long-term effect of the combination of calcium clofibrate and calcium carbonate on serum total cholesterol, triglyceride and high density lipoprotein--cholesterol concentrations in hyperlipoproteinaemia. A comparative study with clofibrate. Atherosclerosis. 1979 May;33(1):49-58. doi: 10.1016/0021-9150(79)90197-7. PMID: 223601.
10: Sankaralingam S, Desai KM, Wilson TW. Clofibrate acutely reverses saline- induced endothelial dysfunction: role of calcium-activated potassium channels. Am J Hypertens. 2006 Nov;19(11):1167-73. doi: 10.1016/j.amjhyper.2006.04.005. PMID: 17070430.